Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: Useful tools for preclinical studies of targeted therapies

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Zhang, Xu chao ^a   Zhang, Jingchuan ^b   Li, Ming ^b   Huang, Xiao sui ^a   Yang, Xue ning ^a   Zhong, Wen zhao ^a   Xie, Liang ^b   Zhang, Lin ^b   Zhou, Minhua ^b   Gavine, Paul ^b   Su, Xinying ^b   Zheng, Li ^b   Zhu, Guanshan ^b   Zhan, Ping ^b   Ji, Qunsheng ^b   Wu, Yi long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

EGFR KRAS mutations; FGFR1 amplification; NSCLC; Patient derived NSCLC xenograft

Indexed keywords

GEFITINIB; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CLINICAL ARTICLE; CMET GENE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EGFR GENE; EXON; FEMALE; FGFR1 GENE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; NONHUMAN; ONCOGENE; ONCOGENE K RAS; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; GENETIC VARIATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, SCID; MUTATION; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880028845     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-168     Document Type: Article

References (36)

1. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin 2011, 61:91-112. 10.3322/caac.20102, 21303969.
2. Favaretto AG, Pasello G, Magro C. Second and third line treatment in advanced non-small cell lung cancer. Discov Med 2009, 8(43):204-209.
3. Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C, Gridelli C. Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010, 11(18):2997-3007. 10.1517/14656566.2010.511615, 20701554.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703. 10.1056/NEJMoa1006448, 3014291, 20979469.
5. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J. Establishment of patient-derived Non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008, 14:6456-6468. 10.1158/1078-0432.CCR-08-0138, 18927285.
6. Fiebig HH, Dengler WA, Roth T. Human tumor xenografts: predictivity, characterization and discovery of new anticancer agents. Contrib Oncol. Basel Karger 1999, 54:29-50.
7. Troiani T, Schettino C, Martinelli E, Morgillo F, Tortora G, Ciardiello F. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol 2008, 65:200-211. 10.1016/j.critrevonc.2007.10.003, 18389522.
8. Sausville A, Bueger AM. Contribution of human tumor xenografts to anticancer drug development. Cancer Res 2006, 66:3351-3354. 10.1158/0008-5472.CAN-05-3627, 16585151.
9. Daniel V, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parminiani G, Dorsch M, Peacock CD, Watlins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009, 69(8):3364-3373. 10.1158/0008-5472.CAN-08-4210, 2821899, 19351829.
10. Frees KK, Tuveson DA. Maximizing mouse cancer models. Nat Rev Cancer 2007, 7:645-658. 10.1038/nri2136, 17687385.
11. Voskoglou-Nomilos T, Pater JL, Seymous L. Clinical predictive value of the in vitro cell line, human xenograft and mouse allograft preclinical cancer models. Clin Cancer Res 2003, 9:4227-4239.
12. Hammer S, Sommer A, Fichtner I, Becker M, Rolff J, Merk J, Klar U, Hoffmann J. Comparative profiling of the novel Epothilone, sagopilone, in xenografts derived from primary Non-small cell lung cancer. Clin Cancer Res 2010, 16:1452-1465. 10.1158/1078-0432.CCR-09-2455, 20179216.
13. Jin K, Teng L, Shen Y, Ke K, Xu Z, Li G. Patient-derived huan tumor tissue xenografts in immunodeficient mice: a systematic review. Clin Trans Onol 2010, 12:473-480.
14. Merk J, Rolff J, Becker M, Leschber G, Fichtner I. Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?. Eur J Cardiothorac Surg 2009, 36:454-459. 10.1016/j.ejcts.2009.03.054, 19502076.
15. Tentler JJ, Bradshaw-Pierce EL, Serkova NJ, Hasebroock KM, Pitts TM, Diamond JR, Fletcher GC, Bray MR, Eckhardt SG. Assessment of the In vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clin Cancer Res 2010, 16(11):2989-2998. 10.1158/1078-0432.CCR-10-0325, 20406842.
16. Hylander BL, Pitoniak R, Penetrante RB, Gibbs JF, Oktay D, Cheng J, Repasky EA. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Translational Med 2005, 3:22.
17. Cutz J-C, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ. Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes. Clin Cancer Res 2006, 12:4043-4054. 10.1158/1078-0432.CCR-06-0252, 16818704.
18. Milne NA, Sitarz R, Carvalho R, Polak MM, Ligtenberg M, Pauwels P, Offerhaus GJ, Weterman M. Molecular Analysis of primary gastric cancer, corresponding xenografts and two novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis. Human Pathol 2007, 19:141-154.
19. Crescenzi M, Persano L, Esposito G, et al. Vandetanib improves anti-tumor effects of L19mTNFa in xenograft models of esophageal cancer. Clin Cancer Res 2011, 17:447-458. 10.1158/1078-0432.CCR-10-1420, 21106730.
20. Huynh H, Soo KC, Pierce KH, Chow PK, et al. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006, 12:4306-4314. 10.1158/1078-0432.CCR-05-2568, 16857806.
21. Tentler JJ, Tan AC, Weekers CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumor xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012, 9:338-350. 10.1038/nrclinonc.2012.61, 22508028.
22. John T, Kohler D, Pintilie M, et al. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage Non -small cell lung cancer. Clin Cancer Res 2011, 17:134-141. 10.1158/1078-0432.CCR-10-2224, 21081655.
23. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010, 2(62):62ra93. 10.1126/scitranslmed.3001451, 21160078.
24. Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, Fan S, Yin X, Xu Y, Liu K, Dong Z, Zhu G, Qian Z, Tang L, Zhan P, Ji Q, Kilgour E, Smith PD, Brooks AN, Thomas RK, Gavine PR. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res 2012, 18(24):6658-6667. 10.1158/1078-0432.CCR-12-2694, 23082000.
25. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong K-K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711. 10.1038/onc.2008.109, 2748240, 18408761.
26. Park B, Jeong BC, Lee KS. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci 2013, 104(5):631-638. 10.1111/cas.12123, 23384396.
27. Chaudary N, Pintilie M, Schwock J, Dhani N, Clarke B, Milosevic M, Fyles A, Hill RP. Characterization of the tumo-microenvironment in patient-derived cervix xenografts (OCICx). Cancers 2012, 4:821-845.
28. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M. Inhibitor-sensitive FGFR1 amplification in human Non-small cell lung cancer. PLoS One 2011, 6:e20351. 10.1371/journal.pone.0020351, 3110189, 21666749.
29. Takafumi K, Hiromasa Y, William WL, Llse V, Junichi S, Michael P, Masaru J, Hiroki O, Tetsuya F, Mamoru O, Nagio T, Katsuyuki K, Kenji S, Hiroshi D, John DM, Marileila V-G, Wan LL, Adi FG, Shinichi T. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer. 2009, 124(8):1778-1784. 10.1002/ijc.24150, 2767331, 19117057.
30. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiating of EGFR action by c-Met. Oncogene 2011, 1-11.
31. Judde JG, Rebucci M, Vogt N, Cremoux P, Livartowski A, Chapelier A, Tran-Perennou C, Boye K, Defrance R, Poupon MF, Bras-Goncalves RA. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer 2007, 120:1579-1590. 10.1002/ijc.22364, 17205515.
32. Katzel JA, Fanucchi MP, Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2009, 2:2. 10.1186/1756-8722-2-2, 2637898, 19159467.
33. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497. 10.1126/science.1099314, 15118125.
34. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Briannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N England J Med 2004, 350:2129-2139.
35. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sruiranpong V, Chao TY, Nakagawa K, Chu DT, Duffield EL SN, Rulazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell ling cancer in Asia (IPASS). J Clin Oncol 2011, 29(21):2866-2874. 10.1200/JCO.2010.33.4235, 21670455.
36. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M. Gefitinib versus cisplatin plus decetaxel in patients with non-smal-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010, 11:121-128. 10.1016/S1470-2045(09)70364-X, 20022809.